Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

2 recruiting

Phase 1

3(60.0%)

N/A

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 1(3)

N/A(1)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Role: lead

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

Role: lead

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

Role: lead

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer

Role: lead

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors

Role: lead

All 5 trials loaded